Abcodia Ltd is a clinical stage company engaged in the commercial development of novel tests for the early detection of cancer. The Company’s first product is the ROCA® Test for the early detection of ovarian cancer, and it is expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer. Abcodia’s offerings are based on expertise in measuring and modelling dynamic changes over time of clinical variables including test results from serum-based markers before cancer is clinically diagnosed. The company maintains exclusive commercial access to a biobank of five million serum samples donated from more than 200,000 individuals over a 10-year period and works collaboratively with academic and industry partners to make use of this unique resource for innovative research and development.
Abcodia is a privately held company funded through investments from Albion Ventures, Cambridge Innovation Capital, Scottish Equity Partners and UCL Business. The company is headquartered in U.K. For more information, visit www.abcodia.com.
About the ROCA® Test
Abcodia’s first product, the ROCA® Test indicates a woman’s likelihood of having ovarian cancer. The ROCA Test is intended for postmenopausal women aged between 50 and 85, or for certain women between 35 and 85 years of age who are considered to have a high lifetime risk of ovarian cancer indicated by family history or testing positive for mutations in certain genes, for example, the BRCA1 or BRCA2 genes. The ROCA Test is equivalent to the Risk of Ovarian Cancer Algorithm (ROCA) that has been evaluated as part of a multimodal screening strategy in several prospective clinical trials in both the U.K. and U.S. involving more than 215,000 women over the past 15 years. The results of those studies show that ROCA, when used with appropriate transvaginal ultrasound as the follow up test, has a higher performance than other currently available methods that have been evaluated prospectively in healthy women. In the clinical studies, ROCA detected the majority of ovarian cancer cases before the first signs or symptoms of ovarian cancer appear.
The ROCA Test is CE marked and is currently available via select gynaecological oncologists working privately in the UK.